Skip to main content

Advertisement

Table 2 Characteristics of patients with GT3-HCV infection who experienced viral relapse after stopping sofosbuvir containing treatment regime

From: Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

No. Age Gender Route of Infection HCV RNA ALT AST TBil PLT Cirrhosis FIB-4 APRI Treatment
Strategy Actual Duration
1 48 M Unknown 4.34 73 87 18.4 132 no 3.70 1.65 SOF + DCV 12
2 50 M Travenous drug abuse 6.30 46 70 16.2 117 no 4.41 1.50 SOF + DCV 12
3 25 F Travenous drug abuse 6.54 52 84 17.7 152 no 1.92 1.38 SOF + DCV 12
4 73 M Blood products 4.16 155 217 29.5 32 yes 39.76 16.95 SOF + DCV 24
5 35 M Travenous drug abuse 6.85 24.6 47.7 28.2 34 yes 9.90 3.51 SOF + DCV + RB 12
6 37 M Unknown 7.35 72.1 115.8 29 182 yes 2.77 1.59 SOF + DCV + RB 12
7 36 M Travenous drug abuse 6.98 331 221 29.1 82 yes 5.33 6.74 SOF + DCV 24
8 41 M Travenous drug abuse 6.53 124 144 17.3 82 yes 6.47 4.399 SOF + DCV 12
9 43 F Travenous drug abuse 6.00 100 100 13.2 34 yes 12.65 7.35 SOF + DCV 12
10 48 F Blood products 7.06 81 122.8 12.6 59 no 11.10 5.20 SOF + DCV 12